Fount of Information

ACROBiosystems社 CD19 a validated therapeutic target for B-cell malignancies

CD19_a_validated_therapeutic_target_for_B-cell_malignancies_1.png

CD19：a validated therapeutic target for B-cell malignancies

CD19_a_validated_therapeutic_target_for_B-cell_malignancies_2.jpg

Product Features

※ Biotinylated, fluorescent-labeled and unconjugated CD19 are available.

※ High bioactivity verified by FACS, SPR and ELISA with protocol offered for free.

※ Suitable for detection of anti-CD19 CAR expression and antibody drug screening.
CD19_a_validated_therapeutic_target_for_B-cell_malignancies_3.jpg Detection of Anti-CD19 CAR Expression by FACS

 1e6 of the anti-CD19 CAR-293 cells were stained with 100 μL of 1:50 dilution (2 μL stock solution in 100 μL FACS buffer) of PE-Labeled Human CD19 (20-291), His Tag (Cat. No. CD9-HP2H3). PE Streptavidin was used as negative control (QC tested)


Protocol >>>
CD19_a_validated_therapeutic_target_for_B-cell_malignancies_4.jpg

High Affinity Verified by SPR

Biotinylated Human CD19 (20-291), His,Avitag (Cat. No. CD9-H82E9) captured on Biotin CAP - Series S sensor Chip can bind FMC63 MAb (mouse lgG2a) with an affinity constant of 0.255 nM as determined in a SPR assay (Biacore 8K) (QC tested)

Protocol >>>

CD19_a_validated_therapeutic_target_for_B-cell_malignancies_5.png

Fount of Information は、新商品、新規取扱メーカーなどの情報をいち早く紹介するコンテンツです。情報発信のスピードを重視しているコンテンツのため、現時点で法規制や取り扱いを確認できていない商品、定価を設定できていない商品があります。ご要望やご照会を受けた商品について、法令整備や在庫の充実を図ります。